Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: A multicenter placebo-controlled study

Hepato-Gastroenterology

Volumn 45, Issue 23, 1998, Pages 1624-1629

  Crosignani, Andrea ^a,c   Budillon, Gabriele ^d   Cimino, Lucia ^d   Del Vecchio Blanco, Camillo ^e   Loguercio, Carmela ^e   Ideo, Gaetano ^c   Raimondo, Giovanni ^f   Stabilini, Roberte ^b   Podda, Mauro ^a  

^a School of Medicine San Paolo   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d Division of Gastroenterology   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

^f Department of Pediatric and Neonatal Surgery   (Italy)

Author keywords

Bile acids; Chronic hepatitis; Tauroursodeoxycholic acid; Therapy; Ursodeoxycholic acid

Indexed keywords

AMINOTRANSFERASE; LIVER ENZYME; TAUROURSODEOXYCHOLIC ACID;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; ENZYME BLOOD LEVEL; FEMALE; HEPATITIS C; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031767456     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Poupon RE, Balkau B, Eschwege E, Poupon R and the UDCA-PBC Study Group: A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324:1548-54.
2. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al: The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19:1149-56.
3. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, et al: Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106:1284-90.
4. Combes B, Carithers RL Jr., Maddrey WC, Lin D, McDonald MF, Wheeler DE, et al: A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22:759-66.
5. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote J: Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113:884-90.
6. Armstrong MJ, Carey MC: The hydrophobic-hydrophilic balance of bile salts. Inverse correlation between reverse-phase high perfomance liquid Chromatographic mobilities and micellar cholesterol-solubilizing capacities. J. Lipid Res 1982; 23:70-80.
7. Attili AF, Angelico M, Cantafora A, Alvaro D, Capocaccia L: Bile acid induced liver toxicity: Relation to the hydrophobic-hydrophylic balance of bile acids. Medical Hypotheses 1986; 19:57-69.
8. Akashi Y, Miyazaki H, Yanagisawa J, Nakayama F: Bile acid metabolism in cirrhotic liver tissue: Altered syntesis and impaired hepatic secretion. Clin Chim Acta 1987; 2:199-206.
9. Attili AF, Rusticali A, Varriale M, Carli L, Repice AM: The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial. J Hepatol 1994; 20:315-20.
10. Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hubner K: Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig Dis Sci 1985; 30:642-9.
11. Podda M, Ghezzi C, Battezzati PM, Crosignani A, Zuin M, Roda A: Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. Gastroenterology 1990; 98:1044-50.
12. Crosignani A, Battezzati PM, Setchell KDR, Camisasca M, Bertolini E, Roda A, et al: Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis; a dose-response study. Hepatology 1991; 13:339-44.
13. Takano S, Ito Y, Yokosuka O, Ohto M, Uchiumi K, Hirota K, et al: A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994; 20:558-64.
14. Rolandi E, Franceschini R, Cataldi A, Cicchetti V, Carati L, Barreca T: Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. Eur J Clin Pharmacol 1991; 40:473-6.
15. Bellentani S, Podda M, Tiribelli C, Callea F, Marazzi M, Sodde M, et al: Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. J Hepatol 1993:19:459-64.
16. Rodrigues CMP, Kren BT, Steer CJ, Setchell KDR: Tauroursodeoxycholic acid is more effective than ursodeoxycholic acid in increasing liver ursodeoxycholate concentrations and reducing lithocholate formation in the rats. Gastroenterology 1995; 109:564-72.
17. Setchell KDR, Rodrigues CPM, Podda M, Crosignani A: Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis. Gut 1996; 38:439-46.
18. Portincasa P, Palmieri V, Doronzo F, Vendemiale G, Altomare E, Sabba C, et al: Effect of tauroursodeoxycholic acid on serum liver enzymes and dyspeptic symptoms in patients with chronic active hepatitis. Curr Ther Res 1993; 53:521-32.
19. Furio L, Tomaiuolo P, Gatta R, Tomaiuolo M, Talarico S, Beverelli V, et al: Treatment of virus-associated liver cirrhosis with tauroursodeoxycholic acid: evaluation of cytolysis and cholestasis indexes and selected immunologic variables. Curr Ther Res 1994; 55:1355-62.
20. Notarbartolo A, Montalto G, Soresi M, Bascone F: Tauroursodeoxycholic acid in patients with chronic hepatitis C: effect on serum levels of transaminases and gamma glutamyl transpeptidase. Adv Ther 1994; 11:262-8.
21. Angelico M, Del Vecchio C, Nistri A: Effect of tauroursodeoxycholic acid on serum liver enzyme and serum lipid levels in patients with chronic active hepatitis. Curr Ther Res 1995; 56:626-34.
22. Nakai T, Katagiri K, Hoshino N, Hayakawa T, Ohiwa T: Microtubule-independent choleresis and anti-cholestatic action of tauroursodeoxycholate in colchicine treated rat liver. Biochem J 1992; 288:613-7.
23. Tsukahara K, Kanal S, Ohta M, Kitani K: Taurine conjugate of ursodeoxycholate plays a major role in the hepatoprotective effect against cholestasis induced by taurochenodeoxycholate in rats. Liver 1993; 13:262-9.
24. Benz C, Angermuller S, Tox U, Kloters-Plachky P, Riedel HD, Sauer P, et al: Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis and cytolysis in rat hepatocytes. J Hepatol 1998; 28:99-106.
25. Podda M, Crosignani A, Battezzati PM, Buscarini L, Conte D, Notarbartolo A, et al: Tauroursodeoxycholic acid for the treatment of chronic hepatitis: A dose-response study. Hepatology 1995; 22:120A
26. Crosignani A, Battezzati PM, Setchell KDR, Invernizzi P, Covini G, Zuin M, et al: Tauroursodeoxycholic acid for the treatment of primary biliary cirrhosis: A dose-response study. Dig Dis Sci 1996; 41:809-15.
27. Calmus I, Gane P, Rouger P, Poupon R: Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990; 11:12-15.